Margaret Ryan
Endocrinology, Diabetes & Metabolism · Bryn Mawr, PANPI 1093926560
Payments from drug & device makers
Across 270 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$903
- Amgen$486
- Novo Nordisk$391
- Boehringer Ingelheim$345
- AstraZeneca$318
- Sanofi-aventis U.S. LLC$264
- plus $3K from 42 others
What the payments were for
- Food & beverage$5,550100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,563 in reported general payments places this provider in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 18 | $24,027 |
| MounjaroTirzepatide | 16 | $20,359 |
| OzempicSemaglutide | 11 | $18,721 |
| SynthroidLevothyroxine Sodium | 25 | $2,107 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $887 |
| Metformin Hcl ErMetformin Hcl | 30 | $439 |
| Levothyroxine Sodium | 30 | $359 |
| Metformin Hcl | 17 | $264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $345 | $24,02718 claims |
| Lilly USA, LLCMounjaro | $903 | $20,35916 claims |
| Novo NordiskOzempic | $391 | $18,72111 claims |
| AbbVieSynthroid | $262 | $2,10725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Bryn Mawr
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
- Arvind CavaleFeasterville Trevose$662K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.